Anthera Pharmaceuticals, Inc. (ANTH)
-NasdaqGM 0.59 
0.01(1.68%) 10:11AM EDT - Nasdaq Real Time Price
| Prev Close: | 0.60 |
|---|
| Open: | 0.59 |
|---|
| Bid: | 0.58 x 100 |
|---|
| Ask: | 0.60 x 100 |
|---|
| 1y Target Est: | 2.16 |
|---|
| Beta: | 1.35 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.58 - 0.61 |
|---|
| 52wk Range: | 0.49 - 3.21 |
|---|
| Volume: | 127,728 |
|---|
| Avg Vol (3m): | 782,536 |
|---|
| Market Cap: | 90.03M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.59 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ANTHERA PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 20)
- ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors orEDGAR Online(Fri, May 17)
- Anthera Pharmaceuticals Reports 2013 First Quarter Financial ResultsPR Newswire(Mon, May 13)
- ANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 13)
- Q1 2013 ANTHERA PHARMACEUTICALS INC Earnings Release - After Market CloseCCBN(Mon, May 13)
- Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod StudyPR Newswire(Tue, May 7)
- Anthera Announces First Quarter 2013 Financial Report and Conference CallPR Newswire(Fri, May 3)
- Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing FacilityPR Newswire(Fri, Apr 5)
- ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a MaterialEDGAR Online(Fri, Apr 5)
- ANTH's Blisibimod Enters Phase IIIZacks(Mon, Apr 1)
- 4 Healthcare Stock Stories For Weekend Investment Wellnessat Wall St. Cheat Sheet(Thu, Mar 28)
- ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, Mar 28)
- Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with BlisibimodPR Newswire(Wed, Mar 27)
- Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial ResultsPR Newswire(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.25 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.05 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases.
View More